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Summary Lung tumours in the elderly show reduced growth potential; impaired angiogenesis may contribute to this phenomenon. Recent
studies have suggested that the angiogenic potential of a tumour may be inferred by the vascularity measured in histological sections. The
purpose of this study has been to determine whether vascularity is related to age, survival or other clinical parameters in resected non-small-
cell lung cancer (NSCLC). A group of 88 consecutive patients with a follow-up period of at least 5 years was selected. The group exhibited a
wide age range (37-78 years) and similar survival characteristics to those of the general NSCLC population. Tumour sections were stained
with a pan-endothelial antibody (vWF) and vascularity was quantitated, without knowledge of the clinical details, by three methods: highest
microvascular density; average microvascular density; and average microvascular volume. The results were analysed by non-parametric
statistical tests. A correlation was found between all three methods of quantitation. Vascularity was not associated with age, sex, tumourtype,
stage, volume, size (TNM-T) nodal status (TNM-N) or survival. However, survival time was generally longer for patients with higher
vascularity, reaching borderline significance (P = 0.06) for the average microvascular density values. Higher tumour volume (P = 0.02) and
stage (P = 0.05) were associated with lower survival times. Using multivariate survival analysis, tumour volume was the only factor related to
survival. We conclude that vascularity is not associated with age and has no significant prognostic value in NSCLC.
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The incidence of squamous cell lung cancer increases with age,
accounting for approximately 40% ofall lung cancers by the age of
80 years (Bryne and Carney, 1995). Clinical studies have indicated
that lung carcinomas in the elderly show reduced growth rate and
metastatic potential in comparison with those of younger patients
(Ershler et al, 1993; Holmes 1989). This is consistent with the
finding of an inverse relationship between stage and age in non-
small-cell lung cancer (O'Rouke et al, 1987; Teeter et al, 1987).
The formation of new blood vessels, or angiogenesis, has been
shown to be essential for tumour growth and metastasis in experi-
mental animal models (Folkman et al, 1990). In such experimental
models both angiogenic potential and tumour growth are reduced
with age (Yuhas et al, 1974; Kim et al, 1989; Kreisle et al, 1990;
Ershler et al, 1993). It is therefore possible thatangiogenic suppres-
sion may play a part in the reduced growth and metastatic potential
observed in lung tumours ofelderly patients (Ershler et al, 1993).
Intratumoral microvessels can be easily visualized in histolog-
ical sections using immunostaining with endothelium-specific
antibodies. The stained vessels can then be counted by a variety of
methods, the most popular of which is the measurement of the
highest microvascular density or 'hotspot' (Weidner 1993). A
large number of studies have found the highest microvascular
density value to be associated with metastasis and poor survival in
various types oftumours (reviewed by Gasparini, 1994; Craft and
Harris, 1994). These results suggest, therefore, that the angiogenic
potential of a tumour may be inferred by its vascularity. This
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hypothesis is widely accepted, so that vascularity measured in
histological sections using pan-endothelial antibodies is increas-
ingly referred to as 'angiogenesis'. The validity ofthis hypothesis,
however, is questioned by results of several studies that found
either no association between vascularity and prognosis (Hall et al,
1992; van Hoef et al, 1993; Axelsson et al, 1995; Busam et al,
1995; Tahan and Stein, 1995; Morphopoulos et al, 1996) orhighest
vascularity associated with good prognosis (Kainz et al, 1995;
Zatterstrom et al, 1995).
A small number of reports concerning the association between
vascularity, metastasis and survival in non-small-cell lung cancer
have been published. The results are also divided along the same
lines as described above, i.e. the majority of studies found high
vascularity to be associated with poorprognosis (Macchiarini et al,
1992; Yamazaki et al, 1994; Fontanini et al, 1995; Yuan et al,
1995; Giatromanolaki et al, 1996), although one large study
(comprising over 200 patients) found that vascularity had no prog-
nostic value (Mattem et al, 1995).
The objectives of our study have been to determine whether
vascularity in resected non-small-cell lung cancer is associated with
either survival or age. It has previously been suggested that contra-
dictory results in the literature may be explained by variations in
vascularity among blocks taken from the same tumour (van Hoefet
al, 1993; De Jong et al, 1995) and by the methods used to measure
vascularity (Pazouki et al, 1997). As quantitative methods in diag-
nostic pathology must be reliable and straightforward, we have
attempted to clarify this situation by measuring vascularity in a well-
defined group of NSCLC patients, using three different methods.
The patients exhibited a wide age range and similar survival charac-
teristics to those from a larger series previously reported and from
the general NSCLC population (Jefferson et al, 1996).
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MATERIALS AND METHODS
Patients and specimens
A group of88 patients was selected from a larger series ofsurgical
resections for NSCLC performed at the Cardiothoracic Centre,
Liverpool, UK (Jefferson et al, 1996). The patients were chosen
from consecutive operative resections by the following criteria: (a)
complete survival data were available for a follow-up period of at
least 5 years; (b) histological material was available in the form of
at least four formalin-fixed, paraffin-embedded blocks; (c) only
the most common NSCLC cell types, squamous cell or adenocar-
cinomas, would be included; and (d) the number ofpatients had to
be large enough so that the group would show survival characteris-
tics representative ofthe larger series. Although part ofthe aims of
the study was to examine the relationship between age and vascu-
larity, the group chosen by the above criteria had a sufficiently
wide age range (37-78 years), so that no other selection criteria
were used. All patients underwent surgery in 1988. They were
classified by tumour cell type, UICC tumour stage and TNM
staging system (T and N) according to published criteria (WHO,
1982; Hermanek and Sobin, 1987; Mountain, 1993).
From each case, a minimum of four blocks were sectioned and
reviewed by a pathologist (DMC) in order to confirm the diagnosis
and select one block per tumour for the analysis of vascularity.
Blocks were selected on the basis of(i) being representative ofthe
tumour, (ii) containing ample tumour areas and (iii) including
tumour free margins.
Immunocytochemistry
Lung tumour sections were dewaxed in xylene, rehydrated in
ethanol and finally washed in distilled water for 5 min followed by
phosphate-buffered saline (PBS) for 10 min. Endogenous peroxi-
dase was blocked by incubating the sections in 3% hydrogen
peroxide in PBS for 10 min. Sections were then pretreated with
protease XXIV (Sigma) 1 mg ml-' in PBS at 37 °C for 30 min.
This was found to be the optimum antigen retrieval method for
lung tissue. Goat serum (20%) in PBS was used to block non-
specific sites for 20 min, the excess serum removed and the
primary antibody applied. Blood vessels were localized by
immunostaining 5 mm-thick sections with rabbit anti-human von
Willebrand factor (vWF) antibody (Dako. cat. no. A0082) diluted
1:4000 in 20% normal goat serum (NGS). Sections were incubated
with the primary antibody at 4°C overnight and then with the
secondary antibody (biotinylated polyclonal goat anti-rabbit IgG
diluted 1:166 in 20% NGS) for 30 min. The slides were then incu-
bated with the Vectastain ABC-peroxidase reagent from the Elite
amplification kit (Vector cat. no. 6100) for 30 min. Next, they were
washed in PBS for 10 min and then incubated in a freshly prepared
diaminobenzidine substrate (0.08 g in 200 ml PBS/
200 ,ul 3% hydrogen peroxide) for 4 min. Sections were rinsed in
PBS, counterstained with haematoxylin, dehydrated and mounted.
In preliminary experiments, the antibody to CD31 (clone JC/70A
from Dako) was compared to the anti-vWF.
Assessment of vascularity
Two non-consecutive sections were immunostained per block. In
all cases, both histological features and vascularity were similar in
the duplicate sections. Vascularity was assessed by light
microscopy using three different methods of quantitation and
without prior knowledge of patient clinical parameters. These
methods were:
1. Highest microvascular density (h-MVD). Any cell or cell
cluster showing antibody staining was considered to be a
countable microvessel, irrespective ofwhether or not a lumen
was present. Microvessels in sclerotic or necrotic areas within
the tumour or those in adjacent areas ofunaffected lung
parenchyma were not considered in the vessel count. The area
ofhighest microvascular density was located by scanning the
section at 120 x magnification. Microvessels were counted at
200 x magnification using a grid that circumscribed an area of
0.476 mm2. All vessels contained either completely or partly
within the grid were included in the count. Three separate
fields were counted and the highest ofthese three counts was
taken as the h-MVD and expressed as the number ofvessels
per mm2 (Weidner, 1993).
2. Average microvascular density (a-MVD). Using the same
criteria, grid and magnification as above, the number of
microvessels were counted in 18 fields selected randomly
throughout the section. a-MVD was determined by calculating
the mean ofthe 18 values and expressed as the number of
vessels per mm2 + standard deviation.
3. Microvascular volume (MVV). The MVV was calculated by
the conventional stereological method ofpoint counting using
an eyepiece graticule that contained 100 points. Vessels that
coincided with the points were counted in 18 fields selected
randomly across each section (a total of 1800 points) and
the results were expressed as percentage volume, taking the
mean ± standard deviation ofthe 18 values.
All specimens were counted by one observer (LMC) after a
period oftraining and assessment ofthe reliability ofthe counting
methods. This included counting the same (10-15) specimens on
separate occasions (a) in conjunction with two other independent
observers, using a two-headed microscope, (b) by the first
observer alone and (c) by two observers independently.
Calculation of tumour volume
Measurements ofthe maximum tumour diameter in three dimen-
sions were available for 51 patients. These three values were
multiplied to give the 'actual tumour volume'. As often only
one dimension per tumour is available, an 'estimated tumour
volume' was calculated by cubing the largest tumour dimension.
Both actual and estimated tumour volumes were used in the
analyses.
Statistical analyses
As vascularity data were not normally distributed, statistical
analyses were performed by non-parametric tests. Kaplan-Meier
(product estimates) and log-rank tests were used for individual
variables and Cox's proportional haza&ds model was used for
multivariate survival analysis. Details ofthe various tests used are
given under the appropriate experimental sections. All analyses
were carried out using SPSS software (version 6.0, SPSS.
Chicago, IL, USA).
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Figure 1 Sections of non-small-cell lung carcinomas stained with vWF antibody. (A and B) Adenocarcinomas of low and high vascularity respectively. (C and D)
Squamous cell carcinomas of low and high vascularity respectively. Bar = 100 gm for C and 50 gm for A, B and D
RESULTS
Patients
Patient characteristics, shown in Table 1, fell within those of the
general population of surgically treated NSCLC (Jefferson et al,
1996). Ofthe 88 patients, 67% were men, 75% had squamous cell
carcinoma, 57% presented with stage I and 63% without bronchial
or mediastinal nodal involvement. At the time of the analyses, 53
patients were dead and 35 were alive.
Histological features: microvessel staining and
distribution
The protocol adopted to immunostain blood vessels was optimized
using nine specimens of NSCLC and two pan-endothelial anti-
bodies: vWF and CD31. Using the optimal antibody concentration
and incubation times, we found significant differences in the
number of vessels stained depending on the pretreatment of the
sections. Under all conditions examined we found vWF preferable
to CD31 regarding the intensity of staining and number of vessels
detected (results not shown). All subsequent staining was
performed with vWF antibody.
Using the optimal protocol (as described in Materials and
methods), immunostaining with vWF was satisfactory for all the
sections examined and variations in the intensity of the staining
were not evident. The distribution and density of the vessels were
consistent for the duplicate sections of a given block, but great
variation was observed among different tumours. For example,
vessels could be either homogeneously orheterogeneously distrib-
uted throughout the section, the highest vessel density could be at
the periphery ofthe tumour ortowards the centre. These variations
were found for both adenocarcinomas and squamous cell carci-
nomas. Examples of high and low vascularity for both tumour
types are shown in Figure 1.
It has been reported previously that the clinical outcome oforal
squamous cell carcinoma patients appears to be correlated with
different pattems oftumour architecture and blood supply (Lauk et
al, 1989). Therefore, for each tumour we assessed the position of
the highest vascularity area (hotspot). In addition, we graded the
following features: (i) vascularity throughout the tumour; (ii)
vascularity at the edge ofthe tumour; (iii) lymphocyte infiltration;
and (iv) tumour architecture. None ofthese parameters was related
to patient outcome, as determined by the chi-square test (results
not shown).
Correlation between three methods of quantitating
vascularity
Using the Spearman or Kendall correlations, all three measure-
ments of vascularity were found to be significantly associated
(P<0.0001) (Figure 2). The highest correlation occurred between
the two methods that measure density (h-MVD and a-MVD,
r=0.78) and the lowestcorrelation was between the highestdensity
and the volume (h-MVD and MVV, r = 0.52).
Relationship between vascularity, age and other clinical
parameters
Clinicopathological characteristics of the patients and the vascu-
larity of the tumours are presented in Table 1. Applying the
Wilcoxon rank-sum test, tumour vascularity, assessed by any of
the three methods used, was not associated with age, sex, tumour
type, volume, stage, size (TNM-T), nodal status (TNM-N) or
patient outcome. Similarly, age was not associated with any ofthe
parameters examined (Table 1).
Analysis of survival
Assessment of the association between vascularity, age and other
clinical parameters with overall survival was investigated by the
Kaplan-Meier estimates of survival function, with comparisons
made using the log-rank tests (Table 2). The median values were
calculated for all three measures of vascularity (4.4 for MVV,
140.8 for h-MVD, 67.2 for a-MVD), as well as for age (65 years),
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93% or 94% level of confidence; these were nodal status (P =
0.07) and vascularity measured by the a-MVD method (P = 0.06).
Survival was not associated with any of the other
parameters examined, including age and vascularity measured by
either h-MVD or MVV (Table 2). Survival curves according to
median values ofthe three vascularity measurements are shown in
Figure 3. It should be noted that the association between a-MVD
and survival indicated that high vascularity was associated with
good prognosis (Table 2 and Figure 4C).
A multivariate survival analysis was performed with the two
variables found to be individually related to survival time (tumour
volume and stage). In this model, tumour stage ceased to be
150 200 predictive of survival; tumour volume was the only measured
factor related to survival, with a 58% (95% CI 52-65%) relative
increase in hazard for tumours larger than 64 cm3 (P=0.005).
Applying the Kruskal-Wallis test, higher tumour volumes were
significantly associated with greater levels ofnodal status (TNM-N)
(P<0.05) Survival curves according to tumour volume defined by
median groupings are shown in Figure 4.
DISCUSSION
0o- . .e . This study was designed to determine whether vascularity in
* S. resected NSCLC was associated with patient survival or age.
I*. U Accordingly, the patients were selected from a larger series previ-
I im . * ously examined (Jefferson et al, 1996) so that their outcome was
2;;|P-m. * representative of that of the larger series, a prolonged follow-up __________________'________________ period was available and a wide range of ages was included. As
o 50 100 150 200 with the general population of surgically treated NSCLC, the 88
h-MVD patients that we examined fell into two distinct groups with either
high or low median survival. We found that vascularity was not
significantly associated with age, survival or any other clinical
parameter, including tumour type, volume, stage, size (TNM-T) or
nodal status (TNM-N).
It is interesting that survival time was generally longer for
C patients with higher vascularity values, but this association only
,0 reached borderline significance for a-MVD, one of the three
vascularity measurements used (Table 2 and Figure 3). Several
studies have reported that high microvascular density is a good
prognostic indicator in carcinoma of the cervix (Siracka et al,
1988; Revesz et al, 1989; Kainz et al, 1995), and head and neck
*. . * tumours (Zatterstrom et al, 1995). However, the majority of
0l * | . * S w studies have found the opposite, i.e. that high vascularity is an
. indicator of poorprognosis (see Introduction).
_: ...... * * To date, all studies measuring vascularity in NSCLC have
1_4vb p-,C~61 *counted thevessels in the most vascularized area or 'hotspot' either
as density (h-MVD) (Macchiarini et al, 1992; Fontanini et al, 1995;
0 , , Yuan et al, 1995) or as point counting a total of 75 points 0 25 50 75 100 125 (Giatromanolaki et al, 1996). A good correlation has been found
a-MVD between different methods to measure vascularity, including subjec-
tive eye appraisal (Giatromanolaki et al, 1996). However, we have Correlation between different methods of quantitating vascularity. previously reported that different results can be obtained when
ds compared were: microvascular volume (MVV), highest
ilar density (h-MVD) and average microvasculardensity (a-MVD). vascularity is estimated by the microvascular volume, rather than
coefficients (r) were as follows: (A) a-MVD v h-MVD r= 0.78; density (Pazouki et al, 1997). Therefore, in this study we have
h-MVD r= 0.52; (C) MVV v a-MVD r= 0.58. P<0.001 for all groups assessed vascularity by three different methods: two that measure
density, eitherrandomly (a-MVD) orin the 'hotspot' (h-MVD), and
umour volume (36 cm3) and 'estimated' tumour volume one that estimates volume by stereological point counting
These values were used as cut-offpoints for the analyses. throughoutthe section(MVV). Apartfrom thenear-significant asso-
time was significantly associated with tumour stage (P = ciation with survival discussed above, the three measurements of
Itumour volume (bothactual, P = 0.02 andestimated, P = vascularity showed the same lack of association with age, survival
wo other parameters were associated with survival at a andclinicopathological parameters (Tables 1 and 2 andFigure 3).
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Table 1 Vascularity, age and other patient characteristics
Variable Number of cases MVV median (IQR) h-MVD median (IQR) a-MVD median (IQR) Age median (IOR)
All 88 4.4 (3.3-5.5) 140.8 (103-192) 67.2 (47.3-98.7) 65 (61-68)
Age
<65 years 46 4.1 (3.3-5.8) 143 (103-183) 67.2 (56.7-84)
>65 years 42 4.3 (3.5-5.4) 139 (103-212) 65.1 (44.1-105)
Sex
Male 59 4.2 (3.5-5.4) 135 (99-181) 65.1 (44.1-98.8) 66 (61-69)
Female 29 4.3 (3.4-5.8) 145 (116-202) 67.2 (54.6-88.2) 63 (60-68)
Tumour type
Squamous cell 66 4.3 (3.4-6.3) 144 (103-202) 67.2 (50.4-105) 65 (61-68)
Adenocarcinoma 22 3.7 (2.8-4.7) 125 (105-160) 67.2 (44.1-84) 64 (63-69)
Actual tumour volume
<36 cm3 27 4.3 (3.7-5.5) 147 (116-190) 75.6 (58.8-96.6) 63 (57-67)
>36 cm3 24 4.6 (3.2-5.9) 149 (88-234) 67.2 (44.1-120.8) 66 (62-70)
Estimated tumour volume
<64 cm3 30 4.3 (3.8-5.8) 152 (116-200) 77.7 (60.9-111.3) 63 (58-70)
>64 cm3 21 4.6 (2.7-5.5) 135 (86-216) 67.2 (37.8-107.1) 67 (62-69)
Tumour stage (UICC)
50 4.3 (3.2-5.3) 139 (103-185) 67.2 (44.1-90.3) 64 (61-70)
11 14 3.5 (2.4-4.3) 126 (111-183) 60.9 (37.8-111.3) 66 (59-68)
Illa 24 4.6 (3.6-6.5) 145 (105-206) 66.2 (53.6-98.7) 64 (63-68)
TNM-T
Ti 32 4.2 (2.8-5) 145 (103-160) 68.2 (44.1-100.8) 63 (57-68)
T2 46 4.4 (3.2-5.5) 135 (101-193) 67.2 (50.4-84) 65 (62-68)
T3 10 4.3 (3.7-6.5) 191 (110-215) 67.2 (50.4-107.1) 66 (61-71)
TNM-N
NO 55 4.3 (3.5-5.3) 143 (103-193) 67.2 (47.3-99.8) 64 (61-71)
Ni 17 3.8 (2.5-5.9) 117 (108-181) 63 (37.8-94.5) 66 (59-68)
N2 16 4.6 (3.7-5.5) 147 (105-204) 65.1 (56.7-92.4) 64 (63-67)
Outcome
Dead 53 3.9 (3.3-5.8) 135 (99-191) 60.9 (44.1-84) 64 (61-69)
Alive 35 4.3 (3.6-5.2) 147 (112-197) 77.7 (55.7-112.4) 65 (60-68)
Vascularity measurements were: microvascular volume (MVV, as %); highest microvascular density
'density (a-MVD, as vessels mm-2). Age is given in years. IQR = inter-quartile range.
Our results disagree with other studies reporting that h-MVD in possibility of u
NSCLC was significantly associated with histological type, stage survival when'
of disease (Yuan et al, 1995), nodal status (Fontanini et al, 1995; study also con
Yuan et al, 1995; Giatromanolaki et al, 1996) distant metastasis with survival, N
(Macchiarini et al, 1992; Fontanini et al, 1995; Yuan et al, 1995; and survival on
Giatromanolaki et al, 1996) relapse free and overall survival In our study
(Yamazaki et al, 1994; Fontanini et al, 1995; Giatromanolaki et al, any other of th
1996). In contrast, our results agree with those of Mattern et al an association
(1995), who found that h-MVD was not a prognostic indicator for NSCLC (Giatri
metastasis or survival in NSCLC; similarly, Yamazaki et al (1994) (Davidson et a
found that vascularity was not associated with lymph node metas- When reported
tasis in adenocarcinomas. larity values t:
Established prognostic indicators in NSCLC include nodal studies have be
involvement, disease stage and tumour grade (Shimosato, 1995). this association
Recently, a clinical study reviewing over 600 patients found that et al, 1995; Tal
tumour volume was associated with survival (Jefferson et al, age and other 1
1996). In spite of the small number of tumours examined in our forNSCLC (Pe
study, we found that larger tumour volumes were associated with 1994) and cuta
shorter survival times (P<0.02), as well as with nodal status The estimate
(TNM-N) (P<0.05). It is interesting to note that both 'actual' and affected by va
Iestimated' tumour volumes correlated with survival, allowing the used and pretr
(h-MVD, as vessels mm-2); and average microvascular
using estimated tumour volumes in calculations of
only the largest tumour dimension is available. Our
firms that tumour stage is significantly associated
whereas the association between nodal involvement
ily reached borderline significance.
y, age was not associated with vascularity or with
ie parameters tested, including survival. In contrast,
ibetween age and vascularity has been found in
romanolaki et al, 1996) and other types of tumours
al, 1994; Miliaras et al, 1995; Leon et al, 1996).
i, tumours from younger patients had higher vascu-
than those from older patients. However, several
een unable to confirm the statistical significance of
n (van Hoefet al, 1993; Axelsson et al, 1995; Bossi
han and Stein, 1995). A lack ofassociation between
prognostic indicators has previously been reported
endleton et al, 1996), oral carcinoma (Williams et al,
neous melanoma (Busam et al, 1995).
ed vascularity in tissue sections can be significantly
ariations in the methodology, including antibody
reatment of the sections (Busam et al, 1995; our
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Table 2 The association between vascularity, age and other clinical parameters with survival
Variable group Median survival in days Probability of survival (%) Significance of relationship
(number of cases) (95% Cl) between 2 and 5 years to survival time
All patients (88)
Age
<65 years (46)
>65 years (42)
Sex
Male (59)
Female (29)
Tumour type
Squamous cell (66)
Adenocarcinoma (22)
MVV
<4.4 (46)
>4.4 (42)
h-MVD
<140.8 (45)
>140.8 (43)
a-MVD
<67.2 (48)
>67.2 (40)
Actual tumour volume
<36 cm3 (27)
>36 cm3 (24)
Estimated tumour volume
<64 cm3 (30)
>64 cm3 (21)
Tumour stage (UICC)
1(50)
11(14)
Ilia (24)
TNM-T
Ti (32)
T2 (46)
T3 (10)
TNM-N
NO (55)
Ni (17)
N2 (16)
994 (142-1845)
535 (0-1967)
994 (0-2756)
751 (252-1250)
2145 (597-3692)
1005 (0-2334)
592 (0-1522)
810 (0-2344)
1224 (274-2173)
751 (324-1178)
1498 (*,*)
592 (163-1021)
2145 (*,*)
2613 (*,*)
355 (104-606)
2651 (*,*)
348 (298-412)
2230 (*,*)
810(0-1861)
565 (227-904)
2230 (*,*)
565 (22-1108)
643 (12-1274)
2145 (*,*)
614 (0-1377)
205 (163-967)
48.9 40.9
50 40
47.6 45.2
P=0.79
P= 0.47 50.9 37.3
58.6 48.3
P=0.88 50 42.4
45.5 36.4
52.1 41.3
52.4 40.5
P= 0.74
P= 0.35 51.1 35.6
58.1 46.5
P=0.06 45.8 33.3
65 50
P=0.02 66.7 55.6
25 25
P= 0.003 66.7 56.7
19.1 19.1
60
57.1
33.3
65.6
40
36.4
P= 0.05 52
35.7
20.8
P= 0.3 53.1
35.6
27.3
58.2 49
31.3 31.3
35.3 23.5
P=0.07
Medians were used as cut-off values for vascularity measurements (MVV, h-MVD, a-MVD), age and tumour volumes. 95% Cl represents the 95% confidence
intervals; when they are not calculable *,* is entered. The significance of association with survival is from the log-rank test.
unpublished data). Even after careful optimization of the method-
ology, heterogeneity among blocks taken from the same tumour
can significantly affect the microvascular density attributed to a
given tumour (van Hoef et al, 1993; De Jong et al, 1995; Schor et
al, manuscript in preparation). We suggest, therefore, that varia-
tions in methodology and tumour heterogeneity could account for
the contradictory reports regarding the value of vascularity as a
tumour prognostic indicator. In a large tumour, such as most
resected NSCLC, it may be necessary to examine multiple blocks
in order to determine the overall vascularity ofthe tumour.
Vascularity, estimated using pan-endothelial antibodies such as
vWF or CD31, is often referred to as angiogenesis; however, these
antibodies do not distinguish between newly formed (angiogenic)
and pre-existing vessels. Furthermore, as microvascular density in
normal bronchial tissue is similar (h-MVD) or higher (a-MVD)
than that oflung tumours (Schor et al, manuscript in preparation),
there is no evidence that vascularity measured in these tumours
by staining the vessels with a pan-endothelial marker represents
angiogenesis. Specific anti-angiogenic vessel antibodies for
paraffin-embedded tissues are not yet available.
Taken together, our results indicate that vascularity, measured
by eitherdensity or volume ofvessels stained withpan-endothelial
markers, is (a) not a prognostic indicator in NSCLC and (b) not
related to the age of the patients. Our results do not exclude the
possibility that angiogenesis may be important in lung tumours,
but suggest that, if this is the case, vascularity measured by
current methods is not an accurate index of angiogenesis in these
tumours.
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Figure 3 Survival curves according to median vascularity values. Vascularity measurements were: (A) microvascular volume (MVV, as %) <4.4,
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